The most cost-effective course of treatment for cryptococcal meningitis is different than current World Health Organization (WHO) recommendations according to University of Minnesota researchers, and as a result, current policies need to be reviewed.

David Boulware, M.D., M.P.H., Associate Director of Global Health Programs in Internal Medicine, Division of Infectious Diseases & International Medicine, Department of Medicine, recommends a shorter, more cost-effective therapy regimen option for cryptococcal meningitis.

Cryptococcal meningitis is a serious fungal infection of the brain, usually occurring in people with immune system deficiencies such as organ transplantation or HIV/AIDS. Cryptococcal meningitis affects approximately 1 million people per year worldwide and is currently the most common cause of meningitis in Africa.

Read more